GUTS vs RNAC

For growth investors, Cartesian Therapeutics, Inc.

(RNAC) is the stronger pick with -92. 8% revenue growth year-over-year, versus -100. 0% for Fractyl Health, Inc. Common Stock (GUTS). Analysts rate Fractyl Health, Inc. Common Stock (GUTS) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cartesian Therapeutics, Inc.

(RNAC) delivered a total return of -91. 3%, compared to -94. 2% for Fractyl Health, Inc. Common Stock (GUTS). Over 10 years, the gap is even starker: GUTS returned -94. 2% versus RNAC's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cartesian Therapeutics, Inc.

(RNAC) is the lower-risk stock at 2. 03β versus Fractyl Health, Inc. Common Stock's 2. 15β — meaning GUTS is approximately 6% more volatile than RNAC relative to the S&P 500.

By revenue growth (latest reported year), Cartesian Therapeutics, Inc.

(RNAC) is pulling ahead at -92. 8% versus -100. 0% for Fractyl Health, Inc. Common Stock (GUTS). On earnings-per-share growth, the picture is similar: Fractyl Health, Inc. Common Stock grew EPS -14. 8% year-over-year, compared to -52. 6% for Cartesian Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Fractyl Health, Inc.

Common Stock (GUTS) is the more profitable company, earning 0. 0% net margin versus -46. 6% for Cartesian Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GUTS leads at 0. 0% versus -31. 0% for RNAC. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Fractyl Health, Inc.

Common Stock (GUTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GUTS: -94. 2%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.